When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Current therapeutic options for non-small cell lung cancer (NSCLC) are ever-evolving with the possibility of solely immunotherapy-based treatment regimens on the near horizon for certain patients.
Optimizing an extracellular matrix scaffold for ovarian follicle implantation helps create successful bioprosthesis for restoring fertility in sterile mice.
